Consolidated Balance Sheet Details

12 Months Ended

Dec. 31, 2017

Balance Sheet Related Disclosures [Abstract]

Inventory (in thousands)

Inventory consists of the following:



	December 31,
	2017		2016
Raw materials	$	—	$	4,397
Work in process	—		2,650
	$	—	$	7,047

Prior to the termination of the Endo Supply Agreement, the Company maintained inventory to fulfill its obligations to manufacture and supply Endo with Sumavel DosePro. Upon the termination of Endo Supply Agreement in September 2017, the Company no longer engages in contract manufacturing and therefore no longer carries inventory.

Property and Equipment, Net (in thousands)



	December 31,
	2017			2016
Machinery, equipment and tooling	$	—		$	11,011
Construction in progress	—			104
Computer equipment and software	141			78
Leasehold improvements	976			1,372
Furniture and fixtures	407			659
Total	1,524			13,224
Less accumulated depreciation	(1,279		)	(11,514		)
Property and equipment, net	$	245		$	1,710

Other Assets (in thousands)



	December 31,
	2017		2016
Deposits and other	278		376
Prepaid clinical trial costs	3,653		771
	$	3,931	$	1,147

Accrued Expenses (in thousands)



	December 31,
	2017		2016
Accrued product returns	$	—	$	99
Accrued interest payable, current	—		121
Accrued clinical trial costs	8,657		3,657
Other accrued expenses	1,842		2,497
	$	10,499	$	6,374

Other Long-Term Liabilities (in thousands)



	December 31,
	2017		2016
Deferred rent	$	244	$	661
Accrual for end of term fee related to term loan	—		729
Other long-term liabilities	540		—
	$	784	$	1,390